Is antitumour necrosis factor therapy combined with ultraviolet B phototherapy safe?

British Journal of Dermatology

Volumn 162, Issue 5, 2010, Pages 1147-1148

  Di Lernia, V ^a   Albertini, G ^a  

^a Arcispedale S Maria Nuova ^*  (Italy)

Author keywords

Anti TNF; Etanercept; Phototherapy; Psoriasis; Skin cancer

Indexed keywords

CYCLOSPORIN; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

CANCER RISK; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTERMETHOD COMPARISON; LETTER; MEDICAL RESEARCH; PATIENT SAFETY; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; RISK ASSESSMENT; SKIN CANCER; TREATMENT DURATION; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION; UNITED KINGDOM;

COMBINED MODALITY THERAPY; HUMANS; IMMUNOGLOBULIN G; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; ULTRAVIOLET THERAPY;

EID: 77951246866     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09663.x     Document Type: Letter

References (10)

1. Wolf P, Hofer A, Legat FJ et al. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Br J Dermatol 2009 160 : 186 189.
2. Kircik L, Bagel J, Korman N et al. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol 2008 7 : 245 253.
3. Bashir MM, Sharma MR, Werth VP. TNF-α production in the skin. Arch Dermatol Res 2009 301 : 87 91.
4. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005 32 : 2130 2135. (Pubitemid 41587856)
5. Sheppard J, Raza K, Buckley CD. Skin cancer in psoriatic arthritis treated with anti-TNF therapy. Rheumatology 2007 46 : 1623 1624. (Pubitemid 47500587)
6. Patel RV, Clark LN, Lebowl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009 60 : 1001 1017.
7. Ji J, Shu X, Sundquist K et al. Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden. Br J Cancer 2009 100 : 1499 1502.
8. Stern RS, Leibman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. J Natl Cancer Inst 1998 90 : 1278 1284. (Pubitemid 28433472)
9. Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 year cohort study. J Invest Dermatol 2003 120 : 211 216. (Pubitemid 36513069)
10. Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009 23 (Suppl. 2 1 70.